JC10 Rec'd PCT/PTO 2 3 MAR 2005

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV524615435US Express Mail Label Number 23 March 2005 Date of Deposit

Form PTO-1390-MOD U. S. (REV 10-96)	ATTORNEY'S DOCKET NUMBER ON/4-32701A						
TRANSMITTAL LETTER TO 1	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
DESIGNATED/ELECTED O		10/528915					
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED					
PCT/EP03/10675	25 September 2003 (25.09.03)	26 September 2002 (26.09.02)					
TITLE OF INVENTION	ETECTING A MUTATION IN A NUIC	I EIC ACID					
PCR BASED DIAGNOSTIC METHOD OF DI APPLICANT(S) FOR DO/EO/US	ETECTING A MOTATION IN A NOC	LEIC ACID					
DAVID BRYANT BATT							
Applicant herewith submits to the United States D	esignated/Elected Office (DO/EO/US) th	e following items and other information:					
<ol> <li>This is a FIRST submission of items condition.</li> <li>This is a SECOND or SUBSEQUENT submission.</li> <li>This express request to begin national examination until the expiration of the application.</li> <li>A proper Demand for International Prelimination.</li> </ol>	bmission of items concerning a filing uni- kamination procedures (35 U.S.C. 371(f) plicable time limit set in 35 U.S.C. 371(b	) at any time rather than delay					
5. A copy of the International Application as a. is transmitted herewith (required b. A has been transmitted by the International Application as		8)					
6. A translation of the International Applicat	ion into English (35 U.S.C. 371(c)(2)).						
<ol> <li>Amendments to the claims of the Interna</li> <li>a.     are transmitted herewith (require</li> </ol>	tional Application under PCT Article 19 ( d only if not transmitted by the Internatio						
<ul> <li>b.  have been transmitted by the Interest of the Int</li></ul>		uts has NOT expired.					
d. 🖾 have not been made and will not	be made.	,					
<ul> <li>8.  A translation of the amendments to the c</li> <li>9.  An executed Declaration and Power of A</li> </ul>	ttorney (original or copy) (35 U.S.C. 371	(c)(4)).					
10. A translation of the annexes to the Intern 371(c)(5)).	ational Preliminary Examination Report	under PCT Article 36 (35 U.S.C.					
Items 11. to 16. below concern document(s) or information included.							
11. 🛛 An Information Disclosure Statement und	der 37 CFR 1.97 and 1.98.						
12.   An assignment document for recording.	A separate cover sheet in compliance w	ith 37 CFR 3.28 and 3.31 is included.					
13. A FIRST preliminary amendment.  A SECOND or SUBSEQUENT prelimina	ry amendment.						
14. An Application Data Sheet under 37 CFF	R'1.76.						
15. A substitute specification.							
16. A change of power of attorney and/or ad	dress letter.						
17. A computer-readable form of the sequen	ce listing in accordance with PCT Rule 1	3ter.2 and 37 CFR 1.821-1.825.					
18.  A second copy of the published Internation	onal Application under 35 U.S.C. 154(d)	(4).					
19.   A second copy of the English language to	ranslation of the International application	under 35 U.S.C. 154(d)(4).					
20.  Other items or information: Unsigned De	eclaration						

## JC14 Rec'd PCT/PTO 23 MAR 2005

U.S. APPLICATION NO	(if known, s	PACFED.5)	15		RNATIONAL APPLICATION NO.  T/EP03/10675				TTORNEY'S E DN/4-3270	Y'S DOCKET NUMBER				
The following fe			n // _								CULATIO	NS PTO USE		
										ONLY	<del></del>	<del></del>		
21. 🛛 Basic national fee														
22. Examination Fee														
If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)														
<u></u>									<b>#200</b>					
⊠ All other situations														
23. Search fee														
☐ If Search fee (37 CFR 1.445(a)(2)) has been paid on the international														
application to the USPTO as an International Searching Authority \$  ☑ If International Search Report was prepared and provided to the Office \$400							\$400							
All other situations														
			TC	TAL OF	21, 22 AND 23 =				•	\$	900			
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer														
program listing f thereof.	program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction													
Total Sheets	Extra	sheets	Num	ber of ea	ach additional 50 or fracti	on		RAT	E	Ι				
47 400 -		150 -	there	of (roun	d <b>up</b> to a whole number)		X	\$	250	\$				
17 - 100 =		/50 =						<b>a</b>	250	1-2				
Surcharge of \$1										\$				
months from the CLAIMS	eaniest		BER FIL		NUMBER EXTRA	T		RATE						
Total claims		9		- 20 =	0	×			50	\$				
Independent cla		5 T CLAIM(S	il (if an	-3 =	2	×	<u> </u>		200 360	\$ \$	400			
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360  TOTAL OF ABOVE CALCULATIONS =								\$	1,300	· · · · · · · · · · · · · · · · · · ·				
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be														
filed (Note 37 CFR 1.9, 1.27, 1.28).							\$	1,300						
Processing fee of \$130 for furnishing the English translation later than 30 months from the								.,						
earliest claimed priority date (37 CFR 1.492(f)). +							\$ \$	4 200						
TOTAL NATIONAL FEE = Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied							<del> </del>	1,300						
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							\$							
TOTAL FEES ENCLOSED =							\$	1,300						
								mount to	\$					
										De.	refunded charged	\$		
a. A chec	k in the a	amount of	\$		to cover the above fe	es is	enclos	sed.						
b.   Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1,300 to cover the above fees. A duplicate copy of this form is enclosed.														
c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to														
Deposit Account No. 19-0134 in the name of Novartis.														
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.														
Send all correspondence to the address associated with														
Customer No. 001095, which is currently:  Lydia T. McNally														
						11a 1.	IVICIAN	ii y		8	<del></del>			
Novartis		octual Prop	erty					plicant						
Corporate Intellectual Property Reg. No. 36,214 One Health Plaza, Building 104 (862) 778-7898														
East Hanover, NJ 07936-1080														